Arca Biopharma | ABIO - Operating Expenses


Arca Biopharma reported $25.09M in Operating Expenses for its fiscal quarter ending in March of 2025.





Operating Expenses Change Date
Alterity Therapeutics Limited AUD 7.78M 3M Jun/2023
Amgen USD 5.9B 773M Dec/2025
Arca Biopharma USD 25.09M 5.23M Mar/2025
Biogen USD 1.88B 81.4M Sep/2025
Brainstorm Cell Therapeutics USD 3.09M 100K Mar/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Capricor Therapeutics USD 24.98M 6.15M Mar/2025
Cipla INR 60.98B 1.06B Dec/2025
Clal Biotechnology ILS 5.15M 9.47M Dec/2022
Compugen USD 9.78M 90K Sep/2025
CSL USD 5.7B 2.82B Dec/2025
Cytokinetics USD 196.12M 27.43M Dec/2025
Daiichi Sankyo JPY 468.57B 15.34B Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
Grifols EUR 1.77B 22.04M Sep/2025
Laboratory Of America USD 3.13B 32.4M Dec/2025
Myriad Genetics USD 229M 3.4M Sep/2025
Otsuka Holdings JPY 582.9B 113.74B Dec/2025
Pfizer USD 12.91B 79.89B Dec/2025
United Therapeutics USD 804.8M 5.79B Dec/2025